Alligator Bioscience regains cancer asset rights from Janssen
Swedish biotech firm Alligator Bioscience has regained the global rights for tumour-directed immunotherapy ADC-1013 (JNJ-64457107)...
Read More...
Focus:
Sweden
-
![Sobi to acquire emapalumab drug from Novimmune]()
Sobi to acquire emapalumab drug from Novimmune
Swedish Orphan Biovitrum (Sobi) has agreed to buy a newly established firm from Novimmune for...
Read More...
-
![Biomedicum research laboratory]()
Biomedicum Research Laboratory, Karolinska Institute
Biomedicum is one of the largest experimental biomedical research laboratories in Europe.
Read More...
-
Deals this week: Medicines for Malaria Venture, Swedish Orphan Biovitrum, aTyr Pharma
Medicines for Malaria Venture (MMV) has entered a collaboration with Drugs for Neglected Disease initiative...
Read More...
-
AstraZeneca divests Synagis US rights to Sobi for $1.6bn
Swedish Orphan Biovitrum (Sobi) has completed the acquisition of US rights to AstraZeneca’s Synagis (palivizumab)...
Read More...
-
Deals and M&As this week: EQT, Sanofi, Bristol-Myers Squibb
EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through...
Read More...
-
EQT increases offer for Karo Pharma to $694m
Private investment firm EQT has increased its offer for Sweden-based Karo Pharma to Skr6.15bn ($694m),...
Read More...
-
![Bioarctic]()
AbbVie licences BioArctic’s Parkinson’s disease portfolio
Swedish biopharma company BioArctic has secured clearance from US Federal Trade Commission (FTC) to out-licence...
Read More...
-
Deals this week: Swedish Orphan Biovitrum, Vectura
Swedish Orphan Biovitrum (Sobi) has entered an agreement to purchase the US rights for Synagis...
Read More...
-
![Synagis]()
Sobi to buy US rights to AstraZeneca’s Synagis drug for $1.5bn
Swedish biopharmaceutical firm Swedish Orphan Biovitrum (Sobi) has signed agreements to acquire the rights to...
Read More...
Close
Close
Close
Go Top
